To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Bristol Myers raised its revenue outlook for the year after newer medicines outperformed expectations, easing pressure on its portfolio of aging blockbusters https://t.co/ZCYNzH1MfR ...

Core Viewpoint - Celestica, Inc. reported strong third-quarter earnings, exceeding analyst expectations and raising its fiscal 2025 outlook, leading to a significant increase in stock price. Financial Performance - Quarterly earnings per share (EPS) were $1.58, surpassing the analyst estimate of $1.47 by 7.63% [1] - Quarterly revenue reached $3.19 billion, exceeding the Street estimate of $3.01 billion [2] - The company achieved a 28% growth in revenue and a 52% growth in non-GAAP adjusted EPS compared to the previous year [3] Operational Highlights - Celestica reported an adjusted operating margin of 7.6%, marking a new high for the company [4] Future Outlook - The fiscal 2025 revenue outlook has been raised to $12.2 billion from $11.55 billion [4] - The adjusted EPS outlook for fiscal 2025 has been increased to $5.90 from $5.50 [4] Stock Performance - Following the earnings report, Celestica's stock price increased by 9.32%, reaching $329.95 in extended trading [4]

Core Insights - Tesla's Q1 2025 earnings call reveals multiple operational levers available to the company, indicating a diverse strategy for growth and performance enhancement [2] Group 1 - Some operational drivers are already implemented and generating results, while others are still in the planning or development stages [2]